Health

msf.org.uk - August 8, 2014

In a statement released today, the World Health Organization (WHO) declared that West Africa's Ebola epidemic is an "extraordinary event" and now constitutes an international health risk.

"A coordinated international response is deemed essential to stop and reverse the international spread of Ebola," the WHO said in a statement after a two-day meeting of its emergency committee on Ebola.

MSF reaction to WHO Ebola statement

In response, Dr Bart Janssens, Médecins Sans Frontières/Doctors Without Borders (MSF) Director of Operations said:

“Declaring Ebola an international public health emergency shows how seriously WHO is taking the current outbreak but statements won’t save lives

“Now we need this statement to translate into immediate action on the ground. For weeks, MSF has been repeating that a massive medical, epidemiological and public health response is desperately needed to saves lives and reverse the course of the epidemic.

“Lives are being lost because the response is too slow.

ZMapp TM is the result of a collaboration between Mapp Biopharmaceutical Inc. and LeafBio (San Diego, CA), Defyrus Inc. (Toronto, Canada), the U.S. government and the Public Health Agency of Canada (PHAC).

ZMapp TM is composed of three “humanized” monoclonal antibodies manufactured in plants, specifically Nicotiana.  It is an optimized cocktail combining the best components of MB-­‐003 (Mapp) and ZMAb (Defyrus/PHAC).

ZMapp TM was first identified as a drug candidate in January 2014 and has not yet been evaluated for safety in humans.  As such very little of the drug is currently available.  

Any decision to use an experimental drug in a patient would be a decision made by the treating physician under the regulatory guidelines of the FDA.

Mapp and its partners are cooperating with appropriate government agencies to increase production as quickly as possible.

CLICK HERE - ZMapp - Information Sheet (1 page .PDF file)

http://www.mappbio.com/

cnn.com - by By Jacque Wilson and Danielle Dellorto - August 5, 2014

(CNN) -- Two American missionary workers infected with the deadly Ebola virus were given an experimental drug that seems to have saved their lives.

Dr. Kent Brantly was given the medication, ZMapp, shortly after telling his doctors he thought he would die, according to a source familiar with his case. Within an hour, doctors say his symptoms -- labored breathing and a widespread rash -- dramatically improved. Nancy Writebol, another missionary working with Samaritan's Purse, received two doses of the medication and has also shown significant improvement, sources say.

As there is no proven treatment and no vaccine for Ebola, this experimental drug is raising lots of questions.

(READ COMPLETE ARTICLE)